Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Michaël R. Paillasse(Evotec (United States)), Pierre Fons(Evotec (United States))
Cancer Research Communications
November 29, 2022
Cited by 12


Related Papers